Pfizer Clinches $10B Deal For Obesity Drug Maker, Beating Novo In Fierce Bidding War

Pfizer is acquiring obesity drug developer Metsera for $10B, beating out Novo Nordisk after antitrust concerns led Novo to withdraw. The deal gives Pfizer a new foothold in the booming weight-loss drug market as it tries to rebound from earlier obesity drug setbacks. Analysts say the price reflects high expectations for future GLP-1 sales despite long-term pricing uncertainty.